Results of the study are anticipated in the initial quarter of 2013. We are thrilled by the prospect of one day putting 3K3A-APC in doctors’ hands to help reduce the tremendous suffering caused by stroke, said Joseph Romano, chief executive officer of ZZ Biotech.. Clinical trials to test safety of 3K3A-APC in individuals with ischemic stroke Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Study Institute and the University of Southern California , and additional produced by biotech company ZZ Biotech. The scientific trials will test the safety in humans of the experimental drug 3K3A-APC, which has been proven in animal models to reduce brain damage and improve motor abilities after stroke when given in conjunction with a federally approved clot-busting therapy.Involvement in social tasks, looking after employees and their own families, and providing equal possibilities for all employees type the building blocks of the global functions. Mutual respect and cooperation, in addition to environmental security and sustainability are intrinsic elements in every of Boehringer Ingelheim’s endeavors. In 2011, Boehringer Ingelheim achieved net sales around 13.2 billion euro. R&D expenditure available area Prescription Medications corresponds to 23.5 percent of its net sales. 1. Institute for Quality and Effiiciency in Health care.